Piper Sandler analyst Matt O’Brien initiated coverage of Heartflow (HTFL) with an Overweight rating and $38 price target Heartflow is a commercial-stage medical technology company that provides artificial intelligence-powered software to diagnose and guide the treatment of coronary artery disease, the analyst tells investors in a research note. The firm believes the company remains in the early launch stages of the $2.9B plaque analysis market and is well positioned for continued share gains.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HTFL:
- HeartFlow, Inc.: Innovative Technology and Strong Financial Performance Drive Buy Rating
- HeartFlow, Inc.: Positioned for Growth in AI-Powered Coronary Diagnostics with Strong Market Potential
- Innovative AI-Driven Diagnostics Propel HeartFlow, Inc. to Buy Rating
- HeartFlow, Inc. Terminates Credit Agreement with Hayfin
- HeartFlow, Inc. Completes Successful IPO Raising $364 Million